https://sputnikglobe.com/20220317/evaluation-of-russian-sputnik-v-vaccine-in-eu-continues-ema-says--1093970485.html
Evaluation of Russian Sputnik V Vaccine in EU Continues, EMA Says
Evaluation of Russian Sputnik V Vaccine in EU Continues, EMA Says
Sputnik International
BRUSSELS (Sputnik) - The European Medicines Agency (EMA) continues the procedure for a gradual examination of the Russian anti-coronavirus vaccine Sputnik V... 17.03.2022, Sputnik International
2022-03-17T17:38+0000
2022-03-17T17:38+0000
2023-04-12T17:09+0000
european medicines agency
russia
sputnik v vaccine
european union (eu)
https://cdn1.img.sputnikglobe.com/img/105928/43/1059284360_0:294:3978:2532_1920x0_80_0_0_04f18774245d2908ae2ca260a7e3abf0.jpg
At the same time, there is currently no active phase in the examination, it said.Sputnik V has been under review by the EMA since March 2021. Hungary and Slovakia approved the vaccine without waiting for EMA authorisation.Sputnik V, the world's first registered vaccine against the COVID-19 infection, was unveiled on 11 August 2020, following Phase 1 and 2 clinical trials. Phase 3 clinical trial results were published in the Lancet magazine on 2 February 2021. The vaccine is based on a well-studied human adenovirus vector platform. The efficacy of Sputnik V has been proven at 97.6%, based on the analysis of data on the occurrence of the COVID-19 infection among Russians vaccinated with both components from December 2020 to late March 2021.Sputnik V has already been authorised in 71 countries with a total population of more than 4 billion people.
russia
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2022
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
european medicines agency, russia, sputnik v vaccine, european union (eu)
european medicines agency, russia, sputnik v vaccine, european union (eu)
Evaluation of Russian Sputnik V Vaccine in EU Continues, EMA Says
17:38 GMT 17.03.2022 (Updated: 17:09 GMT 12.04.2023) BRUSSELS (Sputnik) - The European Medicines Agency (EMA) continues the procedure for a gradual examination of the Russian anti-coronavirus vaccine Sputnik V, the regulator told Sputnik.
At the same time, there is currently no active phase in the examination, it said.
Sputnik V has been under review by the EMA since March 2021. Hungary and Slovakia approved the vaccine without waiting for EMA authorisation.
Sputnik V, the world's first registered vaccine against the COVID-19 infection, was unveiled on 11 August 2020, following Phase 1 and 2 clinical trials. Phase 3 clinical trial results were published in the Lancet magazine on 2 February 2021. The vaccine is based on a well-studied human adenovirus vector platform. The efficacy of Sputnik V has been proven at 97.6%, based on the analysis of data on the occurrence of the COVID-19 infection among Russians vaccinated with both components from December 2020 to late March 2021.
Sputnik V has already been authorised in 71 countries with a total population of more than 4 billion people.
